Hologic Inc (HOLX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Hologic Inc stock (HOLX) is currently trading at $75.52. Hologic Inc PE ratio is 31.35. Hologic Inc PS ratio (Price-to-Sales) is 4.09. Analyst consensus price target for HOLX is $76.60. WallStSmart rates HOLX as Underperform.
- HOLX PE ratio analysis and historical PE chart
- HOLX PS ratio (Price-to-Sales) history and trend
- HOLX intrinsic value — DCF, Graham Number, EPV models
- HOLX stock price prediction 2025 2026 2027 2028 2029 2030
- HOLX fair value vs current price
- HOLX insider transactions and insider buying
- Is HOLX undervalued or overvalued?
- Hologic Inc financial analysis — revenue, earnings, cash flow
- HOLX Piotroski F-Score and Altman Z-Score
- HOLX analyst price target and Smart Rating
Hologic Inc
📊 No data available
Try selecting a different time range
HOLX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Hologic Inc (HOLX)
HOLX trades 358% above its Graham fair value of $16.39, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Hologic Inc (HOLX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, institutional own.. Concerns around revenue growth and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Hologic Inc (HOLX) Key Strengths (3)
96.51% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong operational efficiency: $23 kept per $100 revenue
Hologic Inc (HOLX) Areas to Watch (7)
Earnings declining -9.20%, profits shrinking
Revenue growing slowly at 2.50% annually
Premium valuation at 4.1x annual revenue
Premium pricing at 3.2x book value
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Decent profitability, keeps $13 per $100 revenue
Supporting Valuation Data
Hologic Inc (HOLX) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 3.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, Operating Margin. Profitability is solid with Operating Margin at 23.00%.
The Bear Case
The primary concerns are EPS Growth, Revenue Growth, Price/Sales. Some valuation metrics including PEG Ratio (1.66), Price/Sales (4.09), Price/Book (3.21) suggest expensive pricing. Growth concerns include Revenue Growth at 2.50%, EPS Growth at -9.20%, which may limit upside. Profitability pressure is visible in Return on Equity at 10.90%, Profit Margin at 13.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 10.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (EPS Growth, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HOLX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HOLX's Price-to-Sales ratio of 4.09x sits near its historical average of 4.08x (57th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 4.1x set in Mar 2026, and 1% above its historical low of 4.06x in Mar 2026.
Compare HOLX with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Hologic Inc (HOLX) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Hologic Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 4.1B with 250% growth year-over-year. Profit margins of 13.2% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 250% YoY, reaching 4.1B. This pace significantly outperforms most MEDICAL INSTRUMENTS & SUPPLIES peers.
ROE of 1090.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Margin expansion: can Hologic Inc push profit margins above 15% as the business scales?
Growth sustainability: can Hologic Inc maintain 250%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Hologic Inc.
Bottom Line
Hologic Inc offers an attractive blend of growth (250% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Hologic Inc(HOLX)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Hologic, Inc. is a medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.